Cam Gallagher Sells 12,500 Shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Stock
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL – Get Rating) President Cam Gallagher sold 12,500 shares of Zentalis Pharmaceuticals stock in a transaction on Thursday, September 15th. The shares were sold at an average price of $25.26, for a total value of $315,750.00. Following the completion of the transaction, the president now owns 454,385 shares of the company’s stock, valued at approximately $11,477,765.10. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.
Zentalis Pharmaceuticals Stock Down 6.0 %
Shares of Zentalis Pharmaceuticals stock traded down $1.52 during trading on Friday, reaching $23.86. 1,679,169 shares of the company were exchanged, compared to its average volume of 648,619. Zentalis Pharmaceuticals, Inc. has a twelve month low of $17.33 and a twelve month high of $87.19. The business has a 50-day moving average price of $28.21 and a 200-day moving average price of $30.44. The firm has a market capitalization of $1.36 billion, a price-to-earnings ratio of -6.20 and a beta of 1.88.
Zentalis Pharmaceuticals (NASDAQ:ZNTL – Get Rating) last announced its quarterly earnings data on Tuesday, August 9th. The company reported ($1.34) EPS for the quarter, missing analysts’ consensus estimates of ($1.21) by ($0.13). On average, equities research analysts forecast that Zentalis Pharmaceuticals, Inc. will post -4.78 EPS for the current fiscal year.
Analyst Upgrades and Downgrades
ZNTL has been the subject of several research analyst reports. Morgan Stanley cut their price objective on Zentalis Pharmaceuticals from $95.00 to $60.00 and set an “overweight” rating for the company in a research report on Thursday, August 11th. Cowen assumed coverage on Zentalis Pharmaceuticals in a research report on Tuesday, July 12th. They set an “outperform” rating for the company. SVB Leerink dropped their target price on Zentalis Pharmaceuticals from $67.00 to $42.00 and set an “outperform” rating for the company in a research report on Wednesday, August 10th. HC Wainwright dropped their target price on Zentalis Pharmaceuticals from $120.00 to $55.00 and set a “buy” rating for the company in a research report on Wednesday, August 10th. Finally, Cowen assumed coverage on Zentalis Pharmaceuticals in a research report on Tuesday, July 12th. They set an “outperform” rating for the company. Nine research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $61.38.
Institutional Investors Weigh In On Zentalis Pharmaceuticals
Institutional investors have recently made changes to their positions in the stock. HighTower Advisors LLC grew its stake in Zentalis Pharmaceuticals by 1.2% in the fourth quarter. HighTower Advisors LLC now owns 30,262 shares of the company’s stock valued at $2,544,000 after acquiring an additional 357 shares during the period. Captrust Financial Advisors grew its stake in Zentalis Pharmaceuticals by 15,160.0% in the first quarter. Captrust Financial Advisors now owns 763 shares of the company’s stock valued at $35,000 after acquiring an additional 758 shares during the period. Rhumbline Advisers grew its stake in Zentalis Pharmaceuticals by 2.3% in the fourth quarter. Rhumbline Advisers now owns 35,448 shares of the company’s stock valued at $2,980,000 after acquiring an additional 782 shares during the period. Assetmark Inc. boosted its position in shares of Zentalis Pharmaceuticals by 337.3% during the second quarter. Assetmark Inc. now owns 1,054 shares of the company’s stock worth $30,000 after buying an additional 813 shares during the period. Finally, Teacher Retirement System of Texas boosted its position in shares of Zentalis Pharmaceuticals by 32.5% during the fourth quarter. Teacher Retirement System of Texas now owns 4,323 shares of the company’s stock worth $363,000 after buying an additional 1,061 shares during the period.
Zentalis Pharmaceuticals Company Profile
Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; Phase 1/2 clinical trial for the treatment of advanced solid tumors as a monotherapy and in an ongoing Phase 1b clinical trial in combination with chemotherapy in patients with platinum resistant ovarian cancer; and Phase 2 monotherapy trial for a tumor agnostic, predictive biomarker.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to firstname.lastname@example.org.
Before you consider Zentalis Pharmaceuticals, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Zentalis Pharmaceuticals wasn’t on the list.
While Zentalis Pharmaceuticals currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.